Allspring Global Investments Holdings LLC Acquires New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Allspring Global Investments Holdings LLC acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 140,273 shares of the company's stock, valued at approximately $3,152,000. Allspring Global Investments Holdings LLC owned 0.29% of Nurix Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. ProShare Advisors LLC increased its holdings in shares of Nurix Therapeutics by 9.1% in the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company's stock worth $176,000 after purchasing an additional 998 shares during the last quarter. ClariVest Asset Management LLC boosted its stake in Nurix Therapeutics by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company's stock worth $1,318,000 after buying an additional 1,766 shares during the period. Public Employees Retirement System of Ohio increased its position in Nurix Therapeutics by 3.7% during the first quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company's stock valued at $747,000 after acquiring an additional 1,820 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Nurix Therapeutics by 299.8% in the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company's stock valued at $95,000 after acquiring an additional 3,424 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Nurix Therapeutics by 25.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,942 shares of the company's stock worth $479,000 after acquiring an additional 4,583 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Needham & Company LLC reiterated a "buy" rating and set a $29.00 price target on shares of Nurix Therapeutics in a report on Monday, October 21st. UBS Group assumed coverage on Nurix Therapeutics in a research report on Thursday, October 24th. They set a "buy" rating and a $35.00 target price for the company. Jefferies Financial Group started coverage on Nurix Therapeutics in a report on Friday, October 11th. They set a "buy" rating and a $41.00 price objective on the stock. Barclays upped their target price on Nurix Therapeutics from $20.00 to $31.00 and gave the company an "overweight" rating in a research report on Monday, July 15th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the company an "overweight" rating in a report on Monday, July 15th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, Nurix Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $29.40.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX traded down $0.09 during midday trading on Wednesday, hitting $25.11. The company's stock had a trading volume of 235,973 shares, compared to its average volume of 883,365. Nurix Therapeutics, Inc. has a 12-month low of $4.96 and a 12-month high of $27.60. The company has a market cap of $1.78 billion, a P/E ratio of -8.66 and a beta of 2.22. The business's 50 day simple moving average is $24.18 and its 200 day simple moving average is $20.14.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). The business had revenue of $12.59 million for the quarter, compared to analysts' expectations of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. On average, sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Christine Ring sold 3,290 shares of the company's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $25.00, for a total transaction of $82,250.00. Following the sale, the insider now owns 24,592 shares of the company's stock, valued at approximately $614,800. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Houte Hans Van sold 3,477 shares of the company's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $21.45, for a total value of $74,581.65. Following the completion of the transaction, the chief financial officer now owns 51,002 shares in the company, valued at approximately $1,093,992.90. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Christine Ring sold 3,290 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $25.00, for a total transaction of $82,250.00. Following the sale, the insider now owns 24,592 shares of the company's stock, valued at approximately $614,800. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 57,207 shares of company stock valued at $1,385,269 over the last quarter. 9.80% of the stock is owned by insiders.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.